scholarly journals The Chick Chorioallantoic Membrane In Vivo Model to Assess Perineural Invasion in Head and Neck Cancer

10.3791/59296 ◽  
2019 ◽  
Author(s):  
Ligia B. Schmitd ◽  
Min Liu ◽  
Christina S. Scanlon ◽  
Rajat Banerjee ◽  
Nisha J. D’Silva
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Perineural Invasion ◽  
Chorioallantoic Membrane ◽  
Chick Chorioallantoic Membrane

Lugol Iodine Staining Test in Early Detection of Head and Neck Cancer

2017 ◽  
Vol 68 (8) ◽  
pp. 1944-1945
Author(s):  
Catalin Stefan ◽  
Gabriel Lostun ◽  
Alexandra Lostun
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Iodine Staining ◽  
Examination Techniques ◽  
Staining Techniques ◽  
Malignant Lesions

Head and neck cancer represents 3% of malignancies, and it is associated with high mortality due to advanced stage diagnosis. In early stages, the symptomatology can either be absent or be very common, misleading the patient who often ignores it. Early diagnosis of head and neck neoplasia is essential for a favorable long-term outcome. Lately new in vivo examination techniques were developed, and older ones have been improved. Today, in vivo staining techniques are an important tool in the diagnostic of head and neck cancer. Lugol iodine staining method provides valuable information concerning the tumor, allowing the surgeon to differentiate premalignant and malignant lesions.

scholarly journals Range probing as a quality control tool for CBCT based synthetic CTs: in vivo application for head and neck cancer patients

2021 ◽  
Author(s):  
Carmen Seller Oria ◽  
Adrian Thummerer ◽  
Jeffrey Free ◽  
Johannes A. Langendijk ◽  
Stefan Both ◽  
...  
Keyword(s):  
Quality Control ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cancer Patients ◽  
Neck Cancer ◽  
Quality Control Tool ◽  
Control Tool

scholarly journals Perineural Invasion and Perineural Tumor Spread in Head and Neck Cancer

2019 ◽  
Vol 103 (5) ◽  
pp. 1109-1124 ◽  
Author(s):  
Richard L. Bakst ◽  
Christine M. Glastonbury ◽  
Upendra Parvathaneni ◽  
Nora Katabi ◽  
Kenneth S. Hu ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Perineural Invasion ◽  
Tumor Spread ◽  
Perineural Tumor Spread

scholarly journals Correction: In Vitro and In Vivo Synergistic Antitumor Activity of the Combination of BKM120 and Erlotinib in Head and Neck Cancer: Mechanism of Apoptosis and Resistance

2020 ◽  
Vol 19 (9) ◽  
pp. 1955-1955
Author(s):  
Abu Syed Md Anisuzzaman ◽  
Abedul Haque ◽  
Dongsheng Wang ◽  
Mohammad Aminur Rahman ◽  
Chao Zhang ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Antitumor Activity ◽  
Head And Neck ◽  
Neck Cancer ◽  
Synergistic Antitumor Activity

Impact of daily anatomical changes on EPID-based in vivo dosimetry of VMAT treatments of head-and-neck cancer

2015 ◽  
Vol 116 (1) ◽  
pp. 70-74 ◽  
Author(s):  
Roel A. Rozendaal ◽  
Ben J. Mijnheer ◽  
Olga Hamming-Vrieze ◽  
Anton Mans ◽  
Marcel van Herk
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
In Vivo Dosimetry ◽  
Anatomical Changes

PO-0942 EXPRESSION OF THE EGFR/HER2/PAKT PATHWAY IN VITRO AND IN VIVO IS AFFECTED BY HYPOXIA IN HUMAN HEAD AND NECK CANCER

2012 ◽  
Vol 103 ◽  
pp. S371
Author(s):  
J. Bussink ◽  
J.H.A.M. Kaanders ◽  
D.L. Wheeler ◽  
A.J. van der Kogel ◽  
M. Iida ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Human Head

Mechanism of perineural invasion in head and neck cancer

2014 ◽  
Vol 118 (6) ◽  
pp. e184
Author(s):  
C. Scanlon ◽  
R. Banerjee ◽  
R.C. Inglehart ◽  
M. Liu ◽  
N. Russo ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Neck Cancer ◽  
Perineural Invasion

Tyrosine kinase profiling guides combined therapeutic strategies in head and neck cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6078-6078
Author(s):  
R. Rodríguez-Barrueco ◽  
M. Ortíz-Ruiz ◽  
J. J. Cruz ◽  
A. Ocana ◽  
A. Pandiella
Keyword(s):  
Head And Neck Cancer ◽  
Head And Neck ◽  
Cell Lines ◽  
Neck Cancer ◽  
Tyrosine Kinases ◽  
Egf Receptor ◽  
Drug Combinations ◽  
Metastatic Setting

6078 Background: Squamous cell carcinoma of the head and neck (SCCHN) is still an incurable disease in the metastatic setting. A particular subgroup of proteins implicated in the head and neck cancer are the tyrosine kinases (TK). Therapeutic inhibition of several of them including the EGF receptor with cetuximab in combination with radiotherapy or chemotherapy has shown to be clinically useful. Beyond EGFR, oncogenic activation of other TKs may be implicated in the genesis/progression of SCCHN. In this context, the identification of the TKs activated in SCCHN is a must in order to adequately target these kinases with already available inhibitors. Methods: Here we have investigated activated tyrosine kinases in head and neck cancer tumors derived from patients using a human phospho protein array for 42 receptor tyrosine kinases (RTK). Western-blot experiments were performed to validate each phospho RTK in tumors from patients. The same approach was followed in a series of head and neck cancer cell lines. In vivo xenografted models were used to study the antiproliferative effect of the combination of specific TK inhibitors against them. Results: TK receptors of the EGF and the VEGF family were the mostly activated in tumors derived from patients. 90% of patients revealed high pEGFR content. In addition, other EGFR/HER family receptors, such as HER3, were also activated (phosphorylated) in samples from patients. These data were corroborated in the SCCHN cell lines. In these cells, other RTK signalling intermediates were also active. Particularly, the Akt and FAK kinases. Combination of the anti-EGFR-HER2 TK inhibitor lapatinib with dasatinib (that targets FAK) was synergistic in vitro. Combination of lapatinib with the anti-VEGFR TK inhibitor pazopanib was inefficient in vitro, but resulted in a better trend in response in the in vivo xenografted models, as compared to the action of the single agents. Conclusions: Rational target drug combinations should be based on the identification of activated TK receptors or downstream signalling molecules. In head and neck cancer combination strategies using anti-EGFR/HER, anti-FAK, and anti-VEGFR compounds increases the action of individual treatments. These results open the door for future clinical development of these drug combinations. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document